VRTX - Vertex Pharmaceuticals Incorporated

VRTX

$438.40 +1.81 (+0.41%) Last updated: Apr 22, 2026 14:57

52-Week Range

$438.40

$362.50 $438.40 $510.77

Fundamentals Overview

Vertex Pharmaceuticals Incorporated is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 28.4 PEG 0.03 P/B 5.96 P/S 9.26

Intrinsic value (DCF)

-3.5% downside vs price

Profitability

Net margin 32.8%

Risk (Beta)

0.37 — lower vol

Earnings & growth

EPS $15.44 Rev +4.9% Profit +10% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 58% confidence Risk: Lower Volatility — Beta 0.37. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: B+ · Sentiment improving (7 upgrades)

Pressures (Sell):

3M vs S&P 500: -5.5%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$111.51B

P/E (TTM)

28.4

EPS (TTM)

$15.44

Dividend Yield

N/A

52-Week Range

$362.50 - $510.77

Volume vs Avg

N/A

Beta

0.37

About

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment o...

Sector: Healthcare

Headquarters: US

Employees: 6,100

IPO Date: Jul 1991

Website: www.vrtx.com

Beta: 0.37 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 9, Equal Weight: 1, Hold: 3, Outperform: 8, Overweight: 7, Sector Perform: 2.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $423.24; current price is $438.40. That’s a -3.5% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric	Value
Valuation
P/E (TTM)	28.4
DCF value (model)	$423.24 (-3.5% vs price)
PEG (TTM)	0.03
P/B (TTM)	5.96
P/S (TTM)	9.26
P/FCF (TTM)	34.91
Liquidity & enterprise
Current Ratio (TTM)	2.9
Quick Ratio (TTM)	2.46
Cash Ratio (TTM)	1.32
Profitability
ROE (TTM)	N/A
ROA (TTM)	N/A
Revenue growth (YoY)	N/A
Net margin (TTM)	32.84%
Gross margin (TTM)	86.28%
Operating margin (TTM)	35.45%
Debt to equity (TTM)	N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for VRTX.

Analyst Sentiment at a Glance

B+ Sentiment Improving

Buy 9Equal Weight 1Hold 3Outperform 8Overweight 7Sector Perform 2

7 upgrades, 0 downgrades

Price Target Consensus

Current $438.40

Median $558.00

Consensus $552.53

Low consensus $441.00

High consensus $612.00

Stock Grades (Institutions)

Institution	Action	Previous Grade	New Grade	Date
Morgan Stanley	maintain	Overweight	Overweight	2026-04-10
Maxim Group	upgrade	Hold	Buy	2026-03-18
Truist Securities	maintain	Buy	Buy	2026-03-11
Citigroup	maintain	Buy	Buy	2026-03-10
Morgan Stanley	maintain	Overweight	Overweight	2026-03-10
B of A Securities	maintain	Buy	Buy	2026-03-10
HC Wainwright & Co.	maintain	Buy	Buy	2026-03-10
Oppenheimer	maintain	Outperform	Outperform	2026-03-10
Canaccord Genuity	maintain	Hold	Hold	2026-02-17
Barclays	maintain	Overweight	Overweight	2026-02-17
HC Wainwright & Co.	maintain	Buy	Buy	2026-02-17
RBC Capital	maintain	Outperform	Outperform	2026-02-13
Stifel	maintain	Hold	Hold	2026-02-13
HC Wainwright & Co.	maintain	Buy	Buy	2026-02-13
Scotiabank	maintain	Sector Perform	Sector Perform	2026-02-13
Oppenheimer	upgrade	Perform	Outperform	2026-02-13
Barclays	upgrade	Equal Weight	Overweight	2026-01-28
UBS	maintain	Buy	Buy	2026-01-26
Evercore ISI Group	maintain	Outperform	Outperform	2026-01-23
RBC Capital	upgrade	Sector Perform	Outperform	2026-01-22
Bernstein	upgrade	Market Perform	Outperform	2026-01-12
Wolfe Research	upgrade	Peer Perform	Outperform	2026-01-06
Leerink Partners	maintain	Outperform	Outperform	2025-12-29
Wells Fargo	maintain	Overweight	Overweight	2025-12-10
Morgan Stanley	maintain	Overweight	Overweight	2025-12-05
Morgan Stanley	upgrade	Equal Weight	Overweight	2025-12-03
UBS	maintain	Buy	Buy	2025-11-07
Barclays	maintain	Equal Weight	Equal Weight	2025-11-04
Stifel	maintain	Hold	Hold	2025-11-04
RBC Capital	maintain	Sector Perform	Sector Perform	2025-11-04